Compare Medpace Holdings Inc (MEDP) vs Williams Companies Inc (WMB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medpace Holdings Inc vs Williams Companies Inc — how do they compare? Medpace Holdings Inc trades at $612.05 (market cap $16.82B), while Williams Companies Inc trades at $72.67 (market cap $88.48B). The key difference: Williams Companies Inc is far larger — about 5.3× Medpace Holdings Inc's market cap, and Williams Companies Inc pays a 2.9% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Medpace Holdings Inc for 14 Days and Williams Companies Inc for 58 Days on average.
| MEDP | WMB | |
|---|---|---|
Market Cap | $16.82B | $88.48B |
Volume | 223,093 | 9,280,680 |
Sector | Health | Energy |
52-Week High | $630.19 | $79.40 |
52-Week Low | $393.42 | $56.51 |
Typical Hold Time | 14 Days | 58 Days |
Enterprise Value | $16.44B | $119.11B |
Dividend Yield | — | 2.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Medpace (MEDP) trades at $602.70, down 0.26% with neutral technical signals. The stock shows strong fundamentals with consistent earnings beats (Q4 2025-Q2 2026) and robust profitability (17.67% net margin, 162.15% ROE). Recent CEO stock sales and mixed institutional activity create near-term uncertainty, though analyst consensus remains positive with a $620.44 price target. The company is scheduled to report Q3 2026 results on October 21, 2026.
MEDP presents a compelling growth story with strong financial metrics, though elevated valuations (P/E 35.41) and insider selling warrant caution. Upside potential exists if Q3 earnings meet expectations, while failure to maintain growth momentum could pressure the stock. The current price near pivot point ($599) suggests balanced risk-reward ahead of earnings.
WMB trades at $72.34, up 1.23% with a bullish technical signal. The company shows strong profitability with 25.18% net income margin and 24.02% ROE, though valuation ratios appear elevated with P/E of 28.82. Recent earnings show mixed results with Q1 2026 beat but Q4 2025 and Q2 2026 misses. Natural gas demand growth from AI data centers provides strategic positioning for future revenue growth.
WMB offers attractive dividend yield with 79% analyst buy ratings and $87.27 consensus target, suggesting 21% upside. Key risks include energy market volatility and high debt levels at $24.74 billion long-term debt. The stock presents opportunity for income investors seeking exposure to resilient midstream energy infrastructure with fee-based revenue model.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →About Williams Companies Inc
Williams is a midstream energy company that owns and operates the large Transco and Northwest pipeline systems and associated natural gas gathering, processing, and storage assets. In August 2018, the firm acquired the remaining 26% ownership of its limited partner, Williams Partners.
Read more on WMB →
